<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118495</article-id><article-id pub-id-type="publisher-id">ACM-44429</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_66068660.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  儿童川崎病的诊治进展
  Advances in the Diagnosis and Treatment of Kawasaki Disease in Children
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>金</surname><given-names>蕊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>春燕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院儿科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3413</fpage><lpage>3417</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  川崎病(Kawasaki disease, KD)是一种自限性的全身性血管炎，好发于冠状动脉，是儿童获得性心脏病的主要病因。近年来川崎病的发病率呈上升趋势，其发病的具体病因、机制还未完全明确，由于其可以发生冠状动脉的损害，所以对其的诊断和治疗尤为重要。本文就川崎病的病因、病理、诊断、治疗和预后进行综述。
   Kawasaki disease (KD) is a kind of self-limited systemic vasculitis, which usually occurs in the coronary arteries and is the main cause of acquired heart disease in children. In recent years, the incidence of Kawasaki disease is on the rise, but the specific etiology and mechanism of the disease are not completely clear. Since it can cause coronary artery damage, it is particularly important to diagnose and treat Kawasaki disease. This paper reviews the etiology, pathology, diagnosis, treatment and prognosis of Kawasaki disease.
 
</p></abstract><kwd-group><kwd>川崎病，病因，诊断，治疗, Kawasaki Disease</kwd><kwd> The Cause</kwd><kwd> Diagnosis</kwd><kwd> Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>川崎病(Kawasaki disease, KD)是一种自限性的全身性血管炎，好发于冠状动脉，是儿童获得性心脏病的主要病因。近年来川崎病的发病率呈上升趋势，其发病的具体病因、机制还未完全明确，由于其可以发生冠状动脉的损害，所以对其的诊断和治疗尤为重要。本文就川崎病的病因、病理、诊断、治疗和预后进行综述。</p></sec><sec id="s2"><title>关键词</title><p>川崎病，病因，诊断，治疗</p></sec><sec id="s3"><title>Advances in the Diagnosis and Treatment of Kawasaki Disease in Children<sup> </sup></title><p>Rui Jin<sup>*</sup>, Chunyan Gao<sup>#</sup></p><p>Department of Pediatrics, Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/12-1572440x5_hanspub.png?20210809171539560" /></p><p>Received: Jul. 4<sup>th</sup>, 2021; accepted: Aug. 2<sup>nd</sup>, 2021; published: Aug. 9<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/12-1572440x6_hanspub.png?20210809171539560" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Kawasaki disease (KD) is a kind of self-limited systemic vasculitis, which usually occurs in the coronary arteries and is the main cause of acquired heart disease in children. In recent years, the incidence of Kawasaki disease is on the rise, but the specific etiology and mechanism of the disease are not completely clear. Since it can cause coronary artery damage, it is particularly important to diagnose and treat Kawasaki disease. This paper reviews the etiology, pathology, diagnosis, treatment and prognosis of Kawasaki disease.</p><p>Keywords:Kawasaki Disease, The Cause, Diagnosis, Treatment</p><disp-formula id="hanspub.44429-formula30"><graphic xlink:href="//html.hanspub.org/file/12-1572440x7_hanspub.png?20210809171539560"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/12-1572440x8_hanspub.png?20210809171539560" /> <img src="//html.hanspub.org/file/12-1572440x9_hanspub.png?20210809171539560" /></p></sec><sec id="s5"><title>1. 前言</title><p>川崎病(Kawasaki disease, KD)是一种急性、自限性的全身性血管炎，主要临床表现为发热、口腔黏膜改变、皮疹、颈部淋巴结肿大、球结膜充血和肢端改变等。KD在世界各国均有发生，以亚裔人群发病率为高，主要发生在5岁以下的儿童，具有性别差异，男性多于女性 [<xref ref-type="bibr" rid="hanspub.44429-ref1">1</xref>]。有流行病学研究显示，近年来KD发病率在许多国家尤其是亚洲国家内呈明显上升趋势，其季节流行性也较为显著 [<xref ref-type="bibr" rid="hanspub.44429-ref2">2</xref>]。本病病理变化为全身性血管炎，好发于冠状动脉。在发达国家，KD已经成为儿童获得性心脏病的主要病因 [<xref ref-type="bibr" rid="hanspub.44429-ref3">3</xref>]。所以对于川崎病的早期诊断及早期干预治疗对于降低儿童心血管疾病的发生率具有重要意义。</p></sec><sec id="s6"><title>2. 病因</title><p>KD的病因不明，流行病学资料提示立克次体、丙酸杆菌、葡萄球菌、链球菌、逆转录病毒、支原体感染等为其病因，但均未能证实。目前认为具有遗传特质的个体在某种感染原的触发下产生了异常的免疫反应是KD的可能机制 [<xref ref-type="bibr" rid="hanspub.44429-ref4">4</xref>]。亚裔人群尤其是日裔的发病率较其他人种明显更高，这可能意味着KD的发病存在基因易感性，宿主的易感基因可能在对感染因素引起的异常免疫级联反应中起重要作用 [<xref ref-type="bibr" rid="hanspub.44429-ref5">5</xref>]。</p></sec><sec id="s7"><title>3. 病理</title><p>KD的病理变化为全身性血管炎，好发于冠状动脉。病理过程主要分为以下几个阶段。病变初期是起始于管腔内的小动脉周围炎症，可以看见以中性粒细胞为代表的炎性细胞浸润。随后出现冠状动脉主要分支全层血管炎，弹性纤维和肌层断裂，可形成血栓和动脉瘤。逐渐动脉炎症消退，血栓和肉芽形成，导致冠状动脉部分或完全阻塞，可引发心梗。数月至数年后，病变逐渐愈合，阻塞的动脉可能再通。</p></sec><sec id="s8"><title>4. 诊断</title><p>目前KD的诊断主要根据发热、球结合膜充血、唇充血皲裂、草莓舌、手足硬性水肿、多形性皮疹、颈部淋巴结肿大等临床表现。但并不是所有患儿均具有上述症状，部分患儿临床表现不典型，导致KD诊断困难。</p><sec id="s8_1"><title>4.1. 完全性川崎病</title><p>经典的完全性川崎病的诊断标准为在发热大于5天的基础上，伴下列5项临床表现中的4项者，并排除其他疾病后，即可诊断为川崎病(① 非化脓性双眼结合膜充血；② 多形性皮疹；③ 急性期掌跖红斑、手足硬肿，恢复期指/趾端膜状脱皮；④ 口唇充血、皲裂，草莓舌；⑤ 非化脓性颈淋巴结肿大) [<xref ref-type="bibr" rid="hanspub.44429-ref6">6</xref>]。如5项临床表现中不足4项者，但超声心动图有冠状动脉损害者，亦可确诊为川崎病。2020年日本的川崎病协作组对川崎病的诊断标准进行了第6次修订，新版指南完全性川崎病的诊断标准为：满足6项临床表现(① 发热；② 非化脓性双眼结合膜充血；③ 皮疹；④ 急性期掌跖红斑、手足硬肿，恢复期指/趾端膜状脱皮；⑤ 口唇充血、皲裂，草莓舌；⑥ 非化脓性颈淋巴结肿大)中的5~6项者，无论是否发生冠状动脉损伤，均可诊断为完全性川崎病；若患儿仅满足上述6项临床表现中的4项，则需冠状动脉超声证实存在冠状动脉损伤，才可诊断为完全性川崎病 [<xref ref-type="bibr" rid="hanspub.44429-ref7">7</xref>]。</p></sec><sec id="s8_2"><title>4.2. 不完全性川崎病</title><p>不完全性川崎病的诊断标准为在发热大于5天的基础上，其他5项临床症状仅满足2~3项，且除外其他疾病 [<xref ref-type="bibr" rid="hanspub.44429-ref6">6</xref>]。婴儿发热 ≥ 7天且无其他原因可以解释者，需要考虑不完全KD的可能 [<xref ref-type="bibr" rid="hanspub.44429-ref3">3</xref>]。</p></sec></sec><sec id="s9"><title>5. 治疗</title><p>KD的治疗目标是降低炎症反应，预防血栓形成。所以对于符合川崎病诊断标准的患者应尽早开始治疗。目前阿司匹林和静脉注射丙种球蛋白(intravenous immunoglobulin, IVIG)仍然是治疗KD的主要药物。IVIG在KD中的成功使用使冠状动脉损害(coronary artery lesion, CAL)的发生率降至约4%，但仍有10%~20%的患儿初次使用IVIG后仍持续发热超过36小时或再次发热，称为IVIG无反应型KD [<xref ref-type="bibr" rid="hanspub.44429-ref1">1</xref>]。</p><sec id="s9_1"><title>5.1. 阿司匹林</title><p>阿司匹林具有抗炎、抗血小板凝集和抗氧化的作用，已用于临床治疗KD很多年 [<xref ref-type="bibr" rid="hanspub.44429-ref8">8</xref>]。目前对于阿司匹林的具体用法还存在争议。在川崎病的急性期，初始剂量美国使用80~100 mg/(kg∙d)，日本、西欧使用30~50 mg/(kg∙d)，研究证实两种方案无差异(IIa类，C级)，在热退48~72小时或病程14天后改为小剂量3~5 mg/(kg∙d)，维持6~8周且冠状动脉恢复正常后停用 [<xref ref-type="bibr" rid="hanspub.44429-ref1">1</xref>]。使用阿司匹林治疗KD的患儿可能出现胃炎、上消化道出血、贫血等不良反应，所以对于阿司匹林的最佳用药剂量和时间也存在争议 [<xref ref-type="bibr" rid="hanspub.44429-ref9">9</xref>]。近年来有多项研究结果均表明，与低剂量阿司匹林相比，中、高剂量阿司匹林在预防CAL发生方面并无优势 [<xref ref-type="bibr" rid="hanspub.44429-ref9">9</xref>]。此外，儿童长期大剂量使用阿司匹林可能诱发瑞氏综合征，所以用药期间应加强对患儿的病情观察，加强对家属的健康教育 [<xref ref-type="bibr" rid="hanspub.44429-ref10">10</xref>]。</p></sec><sec id="s9_2"><title>5.2. 静脉注射免疫球蛋白(Intravenous Immunoglobulin, IVIG)</title><p>IVIG治疗KD的机制目前还不完全清楚，主要与通过Fc受体、淋巴细胞和树状突细胞介导的抗炎作用有关 [<xref ref-type="bibr" rid="hanspub.44429-ref11">11</xref>]。研究证实治疗浓度下的免疫球蛋白可通过抑制免疫应答，降低肿瘤坏死因子的表达，从而降低冠状动脉损害的发生率 [<xref ref-type="bibr" rid="hanspub.44429-ref12">12</xref>]。急性期KD患儿予以IVIG可显著降低冠状动脉损伤的风险 [<xref ref-type="bibr" rid="hanspub.44429-ref13">13</xref>]。2017年美国心脏病协会指出病程10天内诊断KD的患者应尽早使用IVIG，推荐IVIG单剂2 g/kg，10~12小时持续静脉输入 [<xref ref-type="bibr" rid="hanspub.44429-ref1">1</xref>]。但是在病程10天以后诊断的患者，ESR增快或CRP &gt; 30 mg/L伴发热或冠状动脉瘤者，需应用IVIG；无发热、炎性指标正常、冠状动脉正常者，不用IVIG (IIa类，B级) [<xref ref-type="bibr" rid="hanspub.44429-ref1">1</xref>]。使用2 g/kg IVIG的患者，11个月内不宜接种麻疹、腮腺炎、风疹和水痘疫苗。</p></sec><sec id="s9_3"><title>5.3. 糖皮质激素</title><p>糖皮质激素作为经典的抗炎药物，具有很强的抗炎和免疫抑制的作用，在多种血管炎相关疾病的治疗中发挥重要作用 [<xref ref-type="bibr" rid="hanspub.44429-ref14">14</xref>]。糖皮质激素在KD治疗中的应用一直存在争议，一般用于IVIG治疗无效的补救措施。最初的研究认为川崎病患儿应用糖皮质激素会增加冠状动脉瘤的风险 [<xref ref-type="bibr" rid="hanspub.44429-ref15">15</xref>]，从而限制了其在初始治疗中的运用。近年来研究证实糖皮质激素能够缩短KD的热程，降低CAL的风险 [<xref ref-type="bibr" rid="hanspub.44429-ref16">16</xref>]。2017年美国心脏协会首次提出糖皮质激素可用于预估IVIG无反应和冠状动脉瘤高风险患者的初始治疗 [<xref ref-type="bibr" rid="hanspub.44429-ref1">1</xref>]。糖皮质激素在KD的初始治疗中应用泼尼松和甲泼尼龙较多，应用地塞米松的相关研究较少 [<xref ref-type="bibr" rid="hanspub.44429-ref14">14</xref>]。泼尼松剂量多采用1~2 mg/(kg∙d)；甲泼尼龙多选择20~30 mg/(kg∙次)的冲击治疗 [<xref ref-type="bibr" rid="hanspub.44429-ref17">17</xref>]。单次甲泼尼龙冲击联合IVIG治疗不应作为常规方案(III类，B级)；对预估并发冠状动脉瘤或者IVIG无反应高危患者，初始治疗可以考虑糖皮质激素联合IVIG (2 g/kg)以及阿司匹林的治疗方案(IIb类，B级) [<xref ref-type="bibr" rid="hanspub.44429-ref1">1</xref>]。</p></sec><sec id="s9_4"><title>5.4. IVIG无反应的治疗</title><p>KD在急性期虽经积极治疗，但仍有10%~20%的患儿对首次IVIG无反应 [<xref ref-type="bibr" rid="hanspub.44429-ref18">18</xref>]。IVIG无反应患儿CAL的发生率较IVIG敏感的患儿更高，因此对于此类患儿如何使用正确有效的方法治疗以降低CAL的发生率十分重要。对于IVIG无反应患儿的治疗方案尚无统一的标准，但随着近年来不断的深入研究，很多学者发现联合使用糖皮质激素、肿瘤坏死因子(TNF) α抑制剂及钙调神经磷酸酶抑制剂等二、三线药物对IVIG无反应型川崎病效果较好，在一定程度上能降低并发症的发生 [<xref ref-type="bibr" rid="hanspub.44429-ref19">19</xref>]。</p></sec></sec><sec id="s10"><title>6. 预后</title><p>川崎病是自限性疾病，多数预后良好。约有50%~95%的中小冠状动脉瘤可逐渐回缩，应长期随访，若动脉瘤持续存在，有出现狭窄、血栓的可能 [<xref ref-type="bibr" rid="hanspub.44429-ref4">4</xref>]。巨大冠状动脉瘤一般不能恢复到正常 [<xref ref-type="bibr" rid="hanspub.44429-ref20">20</xref>]。此外KD血管病变的转归也未明确，但即使恢复正常，血管壁也可能发生了不可逆的损害，后期有诱发心梗的可能 [<xref ref-type="bibr" rid="hanspub.44429-ref21">21</xref>]。一项日本的回顾性研究结果显示有KD病史的患者相较于普通患者会在冠状动脉风险评分较低时发生急性冠状动脉综合征，且发病年龄更小 [<xref ref-type="bibr" rid="hanspub.44429-ref22">22</xref>]。所以对于川崎病的诊断我们需要更加的严谨，对于治疗需要更加的规范，对于预后和远期的随访需要更加的关注。</p></sec><sec id="s11"><title>7. 展望</title><p>目前对于KD的诊治已经取得了一定的进展，但其具体发病机制还尚未明确，还需要我们未来的不断探索。相信随着对KD发病机制的不断深入研究，对于KD的防治也会取得更进一步的进展。</p></sec><sec id="s12"><title>文章引用</title><p>金 蕊,高春燕. 儿童川崎病的诊治进展Advances in the Diagnosis and Treatment of Kawasaki Disease in Children[J]. 临床医学进展, 2021, 11(08): 3413-3417. https://doi.org/10.12677/ACM.2021.118495</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44429-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Mccrindle, B.W., Rowley, A.H., Newburger, J.W., Burns, J.C., Bolger, A.F., Gewitz, M., et al. (2017) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation, 135, e927-e999. &lt;br&gt;https://doi.org/10.1161/CIR.0000000000000484</mixed-citation></ref><ref id="hanspub.44429-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">杜忠东, 陈笑征. 川崎病流行病学研究进展[J]. 中国实用儿科杂志, 2017, 32(8): 565-569.</mixed-citation></ref><ref id="hanspub.44429-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">林瑶, 李晓惠, 石琳, 杜军保. 2017年版《川崎病的诊断、治疗及远期管理——美国心脏协会对医疗专业人员的科学声明》解读[J]. 中国实用儿科杂志, 2017, 32(9): 641-648.</mixed-citation></ref><ref id="hanspub.44429-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">叶卉初, 杨楠, 侯安存. 川崎病的诊断治疗进展[J]. 临床和实验医学杂志, 2021, 20(2): 222-225.</mixed-citation></ref><ref id="hanspub.44429-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Holman, C., Christensen, K.Y., Belay, E.D., Steiner, C.A., Effler, P.V., Miyamura, J., et al. (2010) Racial/Ethnic Differences in the Incidence of Kawasaki Syndrome among Children in Hawaii. Hawaii Medical Journal, 69, 194-197.</mixed-citation></ref><ref id="hanspub.44429-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ayusawa, M., Sonobe, T., Uemura, S., Ogawa, S., Nakamura, Y., Kiyosawa, N., et al. (2005) Revision of Diagnostic Guidelines for Kawasaki Disease (The 5th Revised Edition). Pediatrics International, 47, 232-234.  
&lt;br&gt;https://doi.org/10.1111/j.1442-200x.2005.02033.x</mixed-citation></ref><ref id="hanspub.44429-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kobayashi, T., Ayusawa, M., Suzuki, H., Abe, J., Ito, S., Kato, T., et al. (2020) Revision of Diagnostic Guidelines for Kawasaki Disease (6th Revised Edition). Pediatrics international, 62, 1135-1138. &lt;br&gt;https://doi.org/10.1111/ped.14326</mixed-citation></ref><ref id="hanspub.44429-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">陈强, 訾慧芬, 侯毅, 杨雯, 赵海燕, 马莹莹. 川崎病的诊治进展[J]. 中国中西医结合儿科学, 2020, 12(5): 387-391.</mixed-citation></ref><ref id="hanspub.44429-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">隋坤鹏, 孙一丹, 王海燕, 曲辉. 川崎病治疗研究的新进展[J]. 医学综述, 2021, 27(1): 110-115.</mixed-citation></ref><ref id="hanspub.44429-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">恽孝利. 阿司匹林临床应用的不良反应分析[J]. 世界最新医学信息文摘, 2019, 19(27): 121-122.</mixed-citation></ref><ref id="hanspub.44429-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Marchesi, A., Tarissi de Jacobis, I., Rigante, D., Rimini, A., Malorni, W., Corsello, G., et al. (2018) Kawasaki Disease: Guidelines of the Italian Society of Pediatrics, Part I—Definition, Epidemiology, Etiopathogenesis, Clinical Expression and Management of the Acute Phase. Italian Journal of Pediatrics, 44, Article No. 102.  
&lt;br&gt;https://doi.org/10.1186/s13052-018-0536-3</mixed-citation></ref><ref id="hanspub.44429-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Lau, A.C., Duong, T.T., Ito, S. and Yeung, R.S.M. (2009) Intravenous Immunoglobulin and Salicylate Differentially Modulate Pathogenic Processes Leading to Vascular Damage in a Model of Kawasaki Disease. Arthritis and Rheumatism, 60, 2131-2141. &lt;br&gt;https://doi.org/10.1002/art.24660</mixed-citation></ref><ref id="hanspub.44429-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">路振, 张玉玲. 小儿川崎病发病机制及临床诊治的研究进展[J]. 医学综述, 2021, 27(10): 1982-1987.</mixed-citation></ref><ref id="hanspub.44429-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">李芳芳, 李崇巍. 川崎病初始治疗应用糖皮质激素的研究进展[J]. 医学综述, 2020, 26(12): 2396-2401.</mixed-citation></ref><ref id="hanspub.44429-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kato, H., Koike, S. and Yokoyama, T. (1979) Kawasaki Disease: Effect of Treatment on Coronary Artery Involvement. Pediatrics, 63, 175-179.</mixed-citation></ref><ref id="hanspub.44429-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Burns, J.C., Hoshino, S. and Kobayashi, T. (2018) Kawasaki Disease: An Essential Comparison of Coronary Artery Aneurysm Criteria. The Lancet Child &amp; Adolescent Health, 2, 840-841.  
&lt;br&gt;https://doi.org/10.1016/S2352-4642(18)30334-1</mixed-citation></ref><ref id="hanspub.44429-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Newburger, J.W., Sleeper, L.A., Mccrindle, B.W., LuAnn Minich, L., Gersony, W., Vetter, V.L., et al. (2007) Randomized Trial of Pulsed Corticosteroid Therapy for Primary Treatment of Kawasaki Disease. The New England Journal of Medicine, 356, 663-675. &lt;br&gt;https://doi.org/10.1056/NEJMoa061235</mixed-citation></ref><ref id="hanspub.44429-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Hashino, K., Ishii, M., Iemura, M., Akagi, T. and Kato, H. (2001) Re-Treatment for Immune Globulin-Resistant Kawasaki Disease: A Comparative Study of Additional Immune Globulin and Steroid Pulse Therapy. Pediatrics International, 43, 211-217. &lt;br&gt;https://doi.org/10.1046/j.1442-200x.2001.01373.x</mixed-citation></ref><ref id="hanspub.44429-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">乐园, 杨曦, 刘桂英. 儿童丙种球蛋白无反应型川崎病治疗进展[J]. 中国医药, 2018, 13(8): 1276-1280.</mixed-citation></ref><ref id="hanspub.44429-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Marchesi, A., Tarissi de Jacobis, I., Rigante, D., Rimini, A., Malorni, W., Corsello, G., et al. (2018) Kawasaki Disease: Guidelines of Italian Society of Pediatrics, Part II—Treatment of Resistant Forms and Cardiovascular Complications, Follow-Up, Lifestyle and Prevention of Cardiovascular Risks. Italian Journal of Pediatrics, 44, Article No. 103.  
&lt;br&gt;https://doi.org/10.1186/s13052-018-0529-2</mixed-citation></ref><ref id="hanspub.44429-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">乔红玉, 张若涵, 钱新宏. 儿童川崎病的研究进展[J]. 心脏杂志, 2020, 32(3): 302-305.</mixed-citation></ref><ref id="hanspub.44429-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Mitani, Y., Tsuda, E., Kato, H., Higaki, T., Fujiwara, M., Ogawa, S., et al. (2019) Emergence and Characterization of Acute Coronary Syndrome in Adults after Confirmed or Missed History of Kawasaki Disease in Japan: A Japanese Nationwide Survey. Frontiers in pediatrics, 7, Article No. 275. &lt;br&gt;https://doi.org/10.3389/fped.2019.00275</mixed-citation></ref></ref-list></back></article>